BioRestorative Therapies, Inc. (OTCMKTS:BRTXQ - Get Free Report)'s stock price was up 1.3% on Monday . The company traded as high as $1.52 and last traded at $1.52. Approximately 25,791 shares were traded during trading, a decline of 100% from the average daily volume of 62,169,492 shares. The stock had previously closed at $1.50.
BioRestorative Therapies Trading Up 1.3%
The firm has a market capitalization of $2.51 billion, a price-to-earnings ratio of -1.43 and a beta of 102.36. The stock's 50 day moving average price is $1.57 and its two-hundred day moving average price is $1.72.
BioRestorative Therapies Company Profile
(
Get Free Report)
BioRestorative Therapies, Inc develops therapeutic products using cell and tissue protocols primarily involving adult stem cells. The company's two core programs are related to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program includes a lead cell therapy candidate, BRTX-100 is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow and intended for the non-surgical treatment of painful lumbosacral disc disorders.
Read More
Before you consider BioRestorative Therapies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioRestorative Therapies wasn't on the list.
While BioRestorative Therapies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
